Pharma rep visits: 66.7% of US clinicians, mostly dermatologists, would turn away a rep who asks to come every two weeks, against 39.4% for a monthly visit
Being asked too often, and their employer: 66.7% of US clinicians on the Brox HCP panel would decline a 10-minute pharma rep visit every two weeks against 39.4% monthly, and 24 of the 36 who no longer see reps name a practice or health system restriction (n=198, November 2026).
- Who was asked
- US clinicians, 198 clones, US
- When
- November 2026 (fielded 9 November 2026)
- How
- Predicted responses from Brox clones, each built from a long-form interview with a real person.
- What changed from the obvious question
- The obvious question lists the reasons doctors give for refusing reps, which industry channel surveys already cover. This study measured a threshold instead: how often one rep can ask to visit before most clinicians decline, then which single reason would make them stop, split by whether they say they already have.
Section 01: What the panel said
- #
66.7%
Asked by a rep for a medicine they already prescribe for a 10-minute in-person visit, 66.2% of US clinicians would agree to one every three months, 58.1% to one a month and 31.8% to one every two weeks; the share who would decline rises from 30.8% to 39.4% to 66.7%.
base 198
- #
24
Of the 36 clones who say they no longer see pharmaceutical sales representatives at all, 24 name a practice or health system restriction as the reason; among the other 162, promotional rather than balanced information leads (49) and a restriction is named by 29.
base 36 · Clinicians who say they no longer see reps at all · contrast
- #
39.9%
39.9% say new head-to-head or real-world outcome data would make a 10-minute rep visit worth their time, 28.3% copay cards or free samples, 21.2% hands-on prior authorization help and 10.6% nothing; only 3.0% would stop seeing reps because they cannot help with coverage or costs.
base 198 · contrast
- #
18.2%
18.2% say they no longer see pharmaceutical sales representatives at all and 41.4% see them in person most weeks, but 163 of the 198 answers to this question were inferred from the clones' interviews rather than stated in them, so it reads as direction, not a measured rate.
base 198 · caveat
Asked by a rep for a medicine they already prescribe for a 10-minute in-person visit, 66.2% of US clinicians would agree to one every three months, 58.1% to one a month and 31.8% to one every two weeks; the share who would decline rises from 30.8% to 39.4% to 66.7%.
02Where does a rep's welcome run out?
Between once a month and once every two weeks. Of the 198 clinicians, 131 would take a 10-minute in-person visit every three months from a rep for a medicine they already prescribe. 16 drop out when the same rep asks monthly, and 52 more when the rep asks every two weeks, so the largest step by far is the last one. Nobody moves back: every clone that declines at a lower frequency also declines at a higher one.
The step is the same in dermatology and outside it. 66.7% of the 126 dermatologists and 66.7% of the 72 other clinicians would decline the fortnightly visit. Even among the 82 clinicians who say they see reps in person most weeks, 32 would turn away one rep asking to come every two weeks.
03Who has already stopped seeing reps, and why?
Mostly clinicians whose employer stopped them. 36 of the 198 clones say they no longer see pharmaceutical sales representatives at all, and 24 of those 36 name a practice or health system restriction as the reason. Their answers describe academic medical centers and integrated health systems that keep reps out of the clinic.
The clinicians who still see reps give a different reason for what would make them stop. Of the other 162, 49 name information that is promotional rather than balanced, 41 the time visits take from patients and 38 the speed of getting the same information online or from colleagues; 29 name a restriction.
04Does help with coverage keep the door open?
It draws clinicians in, but its absence almost never pushes them out. Only 3.0% (n=198) say reps being unable to help with insurance coverage, prior authorization or patient costs would be the reason they stopped. Yet asked what would make a 10-minute visit worth their time, 28.3% name copay cards or free samples and 21.2% hands-on help with a prior authorization, 49.5% between them, against 39.9% for new head-to-head or real-world outcome data.
That fits what other Brox pages found about how clinicians weigh coverage: it is the trigger that moves a new indication into practice (read that page), and a small out-of-pocket gap is enough to move a prescription (read that page).
05What would a field force or omnichannel team do with this?
- Our reading, not the panel's answer: a call plan that asks one clinician for a visit every two weeks is past the point where most say yes; 58.1% (n=198) accept a monthly visit and 31.8% a fortnightly one.
- Our reading: for the clinicians behind a health system restriction, a better rep will not reopen the door, so other channels carry the message there. 24 of the 36 who have stopped name a restriction.
- Our reading: lead a visit with new outcome data and bring access support with it. Data is the single most named draw at 39.9% (n=198), and copay or prior authorization help together reach 49.5%.
06What do people also ask?
- What share of doctors would accept a monthly visit from a pharma rep? 58.1% (n=198) would agree to a 10-minute in-person visit once a month from a rep for a medicine they already prescribe.
- How often can a pharma rep ask to visit before most doctors say no? Every two weeks: 66.7% (n=198) would decline at that frequency, against 39.4% for a monthly visit and 30.8% for one every three months.
- How many doctors who have stopped seeing pharma reps were stopped by their employer? 24 of the 36 clones who say they no longer see reps at all name a practice or health system restriction as the reason.
Section 07: What they said, and the interview line it rests on
“No, I would decline. Every two weeks is far too frequent, and honestly, I don't find detailing visits from pharma reps to be particularly helpful. I know they're coming in with a specific agenda and are very much trying to persuade me in a biased way. If there are updates to prescribing information, new safety signals, or trial data, I keep up with that myself through academic journals like JAAD and JAMA Dermatology or by looking at randomized controlled trial data. With seeing around 30 patients a day in clinic, taking recurring meetings for a medication I already prescribe isn't a good use of time.”
Predicted from this line in the interview
“I don't really find those to be as helpful because I know they're very much trying to persuade me in a certain way, in a very unbiased way, a very biased way.”
“Honestly, the main reason I don't see them in my practice anymore is that our site basically excludes them. My practice and health system restrict reps from coming in, so the only time I ever even cross paths with them nowadays is occasionally grabbing a cookie or snack at a conference.”
Predicted from this line in the interview
“God, not anymore. I think they're excluded from our site.”
“For a visit with a sales rep to actually be worth my time, they would need to bring real, primary clinical data rather than glossy marketing pamphlets. I do not rely on sales pitches or pre-curated summaries to evaluate a treatment; I need to see the actual trial data and raw evidence to assess whether a medication truly offers clinical benefit. Having solid, objective outcome data brought straight to me is the one thing that would genuinely assist my clinical decision-making and potentially help me adopt a therapy faster.”
Predicted from this line in the interview
“Just give you, like, this… the primary data, like, the… the trial data that… like, as opposed to the pamphlets with the already curated information, having the raw material… the raw data would help me adopt it quicker.”
Section 08: How much should you trust this?
What we would defend
- The ladder: stated acceptance of one rep's 10-minute in-person visit falls from 66.2% to 58.1% to 31.8% (n=198) as the request goes from every three months to monthly to every two weeks; every clone moves in one direction only and each rung's reasoning cites its own frequency.
- That the cliff is the same in dermatology and outside it: 66.7% of the 126 dermatologists and 66.7% of the 72 other clinicians would decline the fortnightly visit.
- New outcome data as the most named single draw for a visit, 39.9% (n=198), and coverage help as a draw rather than a deal-breaker: 49.5% name copay or prior authorization help as what makes a visit worth it, 3.0% name its absence as a reason to stop.
What we would not
- 18.2% (n=198) as the national share of clinicians who no longer see reps: 163 of 198 answers to the current-practice question were inferred rather than stated in the interviews.
- 24 of 36 as a measured split of why clinicians stopped: it rests on that same mostly inferred question, though 29 of the 36 reasonings describe an institutional policy.
- A precise tipping frequency: only quarterly, monthly and fortnightly were tested, so most clinicians turn a single rep away somewhere between monthly and every two weeks.
- Any split by age, gender or region: those demographics are missing for most of the 198 clones.
The main limitation
These are 198 clones of US clinicians, two thirds of them dermatologists, stating whether they would accept one written request from one rep for a medicine they already prescribe; stated acceptance is not the number of visits a practice actually takes.
Section 09: How was this run?
| Segment | Clones |
|---|---|
| Dermatology | 126 |
| Another medical specialty | 46 |
| Primary care (family or internal medicine) | 17 |
| Nurse practitioner, physician assistant or pharmacist | 6 |
| A surgical specialty | 3 |
Question wording as fielded
- Which best describes how you handle visits from pharmaceutical sales representatives at your practice today?
- In general, if you stopped seeing pharmaceutical sales representatives altogether, which one reason would most likely be behind it?
- In general, which one thing would a pharmaceutical sales representative have to bring to make a 10-minute visit worth your time?
- A pharmaceutical sales representative for a branded medicine you already prescribe asks for a 10-minute in-person visit at your practice once every three months, to go over updated prescribing information. Would you agree to these visits?
- A pharmaceutical sales representative for a branded medicine you already prescribe asks for a 10-minute in-person visit at your practice once a month, to go over updated prescribing information. Would you agree to these visits?
- A pharmaceutical sales representative for a branded medicine you already prescribe asks for a 10-minute in-person visit at your practice once every two weeks, to go over updated prescribing information. Would you agree to these visits?
What was not asked, and why
No medicine, brand or manufacturer was named. Visits were always 10 minutes, in person, for a medicine the clinician already prescribes, to go over updated prescribing information; a rep for a new launch, a longer visit, a visit with samples, a lunch or a virtual-first request were not tested, and nor was a frequency between monthly and fortnightly. Ask Brox fielded the six questions as written and added one screener of its own (currently authorized to prescribe in the US), which all 198 passed.
What changed from the obvious question
The obvious question lists the reasons doctors give for refusing reps, which industry channel surveys already cover. This study measured a threshold instead: how often one rep can ask to visit before most clinicians decline, then which single reason would make them stop, split by whether they say they already have.
Fielded through Ask Brox on 9 November 2026.
More on How doctors decide what to prescribe · Pharma & HCP · HCP (US) panel
Ask this of your own customers: humans@brox.ai
Related insights
All in this topic-
Medical science liaisons: 60.1% of US physicians and other prescribers want real-world and subgroup evidence for patients like theirs, and 65.2% rate a liaison meeting useful against 17.7% for a sales rep
65.2% 65.2% rate a 20-minute meeting with a medical science liaison at least moderately useful to their practice, against 17.7% for a 20-minute meeting with a sales representative about the same kind of medicine (base 198)
Read -
Patient out-of-pocket cost and prescribing: US physicians keep a preferred brand at $25 a month, split at $75, and 62.9% switch to a generic at $150
37.1% 37.1% (26 of 70) would still prescribe the brand-name medicine they prefer when it costs the patient $150 a month against $5 for an older generic, down from 95.7% (67 of 70) at $25 and 55.7% (39 of 70) at $75; none of the 70 moves back to the brand as the price rises. (base 70)
Read -
New medicine launches: 72.9% of US physicians and other prescribers would try one in its first months when it is covered, 22.9% when patients pay $250 a month
22.9% 22.9% (16 of 70) are likely, a 6 or 7 of 7, to prescribe a new medicine with a clear phase 3 benefit in the next three months when most plans do not cover it and a patient pays about $250 a month, against 72.9% (51 of 70) when it is covered with no prior authorization and a $30 copay, and 54.3% (38 of 70) when prior authorization takes one to two weeks. (base 70)
Read -
Oral JAK inhibitor or biologic: 88.9% of US dermatologists start a pill-seeking eczema patient on the JAK, and only a $150 a month gap tips most to the biologic
88.9% For a healthy 35-year-old with moderate-to-severe eczema who dislikes injections and asks for a pill, 88.9% of US dermatologists would start an oral JAK inhibitor rather than an injectable biologic when both cost the patient $0 a month; 81.7% still would when the JAK costs $30 a month more, 69.0% at $75 more and 46.8% at $150 more. (base 126)
Read